Actionable news
All posts from Actionable news
Actionable news in OCUL: OCULAR THERAPEUTIX Inc,

BTIG Reiterates Buy on Ocular Therapeutix Inc Despite Clinical Setback

Ocular Therapeutix Inc (NASDAQ:OCUL) shares fell more than 50% on Friday, after the company’s most advanced asset, a sustained-release formulation of the anti-inflammatory dexamethasone (branded as Dextenza), came through with mixed results in a Phase III study on allergic conjunctivitis. The company also reported topline results for its phase 2 glaucoma trial, which had equivocal results versus timolol.

Despite the clinical setback, BTIG analyst Hartaj Singh came out today, reiterating a...